ProBioGen AG Patent applications |
Patent application number | Title | Published |
20150299666 | Novel MVA Virus and Uses Thereof - The present invention relates to a novel Modified Vaccinia Ankara (MVA) virus. The present invention also relates to a method for culturing said MVA virus and to a method for producing said MVA virus. Further, the present invention relates to a pharmaceutical composition comprising said MVA virus and one or more pharmaceutical acceptable excipient(s), diluent(s), and/or carrier(s). Furthermore, the present invention relates to a vaccine comprising said MVA virus. In addition, the present invention relates to said MVA virus for use in medicine. | 10-22-2015 |
20140377803 | ENHANCEMENT OF PROTEIN PRODUCTION YIELD MEDIATED BY A FAST SHUTTLING CDC42 GTPASE - The present invention relates to a cell for producing a secreted protein comprising a polynucleotide comprising a nucleic acid sequence encoding a fast cycling cdc42 mutant and a polynucleotide comprising a nucleic acid sequence encoding a secreted protein. It also relates to a method for producing said cell and to a method for producing a secreted protein using said cell. | 12-25-2014 |
20140221627 | METHODS FOR PREPARATION OF FUCOSE-LINKED SITE SPECIFIC CONJUGATES OF PROTEINS WITH TOXINS, ADJUVANTS, DETECTION LABELS AND PHARMACOKINETIC HALF LIFE EXTENDERS - The present invention relates to eukaryotic cells for producing molecules having an atypical fucose analogue on their glycomoieties and/or amino acids. It also relates to methods for producing molecules having an atypical fucose analogue on their glycomoieties and/or amino acids and to molecules obtainable by said methods. It further relates to methods for producing conjugates comprising molecules having an atypical fucose analogue on their glycomoieties and/or amino acids and pharmaceutical active compounds and to conjugates obtainable by said methods. In addition, the present invention relates to specific conjugates. | 08-07-2014 |
20130273636 | DEPLETION OF HOST CELL COMPONENTS FROM LIVE VECTOR VACCINES - It is desirable to produce live vaccines, which are highly attenuated and which do only contain minimal or no animal-derived components. The production of highly attenuated live viruses can be better achieved when using specifically designed cell lines as producer substrate as opposed to using less defined primary cells. However, live viruses, thus produced comprise undesirable components from the cell lines and cell culture. The present invention relates to methods of production and purification of live enveloped viruses, which are suitable for vaccination. | 10-17-2013 |
20120288916 | IMMORTALIZED AVIAN CELL LINES FOR VIRUS PRODUCTION - The present invention relates to immortalized avian cell lines suitable for production of biologicals or viruses for vaccination. In particular, the cell lines are derived from primary cells which are transformed with at least two viral or cellular genes, one of which causes cell cycle progression whereas the other interferes with innate protective mechanisms of the cell induced by dysregulated replication. The invention moreover relates to the production of said immortalized cell lines and their use for producing biologicals or viruses for vaccination. | 11-15-2012 |
20120164727 | PRODUCTIVITY AUGMENTING PROTEIN FACTOR, NOVEL CELL LINES AND USES THEREOF - The present invention provides a method for preparing a non-adenoviral target virus or target proteins utilizing a potent expression cell line having stably integrated into its genome a gene encoding a specific heterologous regulator protein. | 06-28-2012 |
20110269116 | Cell Line From Rousettus As Host Cell For Pathogen Amplification - The present invention relates to permanent cell lines from chiropterans suitable for amplification and production microbial agents, preferably viruses, and its use for diagnostic or therapeutic purposes. | 11-03-2011 |
20090155895 | LIQUID-GAS-PHASE EXPOSURE REACTOR FOR CELL CULTURING - Initiation of growth and cultivation of cells can be performed by introducing the cells into culture compartments of a liquid-gas-phase exposure bioreactor containing a supply chamber in which there are disposed hollow-filament membranes having an inside diameter of no larger than 5 mm, wherein an inner volume of said hollow-filament membranes forms the culture compartments. Approximately one half of the supply chamber is filled with a nutrient medium and a remainder is filled with a gas mixture. Perfusion of medium and gas is turned on simultaneously or separately. The hollow-filament membranes and the cells contained therein are cyclically exposed to the gas or liquid phase. | 06-18-2009 |